Quick Answer
Krystal Biotech, Inc. reported Stockholders Equity of $1.22 billion for the year ending 2025.
- Krystal Biotech, Inc. showed an increase of +28.9% in Stockholders Equity from 2024 to 2025.
- This data is from Krystal Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $50.20 million | Q1 2018: $47.40 million | Q2 2018: $45.27 million | Q3 2018: $52.29 million | Q1 2019: $109.49 million | Q2 2019: $198.29 million | Q3 2019: $207.65 million | Q1 2020: $198.37 million | Q2 2020: $309.70 million | Q3 2020: $301.72 million | Q1 2021: $430.65 million | Q2 2021: $418.54 million | Q3 2021: $408.24 million | Q1 2022: $548.55 million | Q2 2022: $559.18 million | Q3 2022: $540.77 million | Q1 2023: $489.57 million | Q2 2023: $653.11 million | Q3 2023: $755.95 million | Q1 2024: $799.24 million | Q2 2024: $838.89 million | Q3 2024: $885.85 million | Q1 2025: $984.67 million | Q2 2025: $1.04 billion | Q3 2025: $1.14 billion.
- Over the full 10 years of available data (2016 to 2025), Krystal Biotech, Inc.'s Stockholders Equity has grown by 421,893.1%.
- Historical annual values: Fiscal year 2025: $1.22 billion | Fiscal year 2024: $946.38 million | Fiscal year 2023: $778.64 million | Fiscal year 2022: $522.23 million | Fiscal year 2021: $593.58 million | Fiscal year 2020: $292.08 million | Fiscal year 2019: $202.91 million | Fiscal year 2018: $113.23 million | Fiscal year 2017: $49.47 million | Fiscal year 2016: $289.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: